Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.